THE-EARTHSHOT-PRIZE
17.9.2021 19:03:10 CEST | Business Wire | Press release
The Earthshot Prize announces today its first-ever shortlist of 15 Finalists, each with a chance of winning £1million to support their innovative environmental solutions to the greatest challenges facing the planet.
Prince William said: "Over half a century ago, President Kennedy’s ‘Moonshot’ programme united millions of people around the goal of reaching the moon. Inspired by this, The Earthshot Prize aims to mobilise collective action around our unique ability to innovate, problem solve and repair our planet.
“I am honoured to introduce the 15 innovators, leaders, and visionaries who are the first ever Finalists for The Earthshot Prize. They are working with the urgency required in this decisive decade for life on Earth and will inspire all of us with their optimism in our ability to rise to the greatest challenges in human history.”
Launched by Prince William and The Royal Foundation in October 2020, The Earthshot Prize is the most prestigious global environment prize in history. Like President John F. Kennedy’s ‘Moonshot’ did almost 60 years ago, the Prize aims to unleash an unprecedented wave of innovation and leadership to tackle our greatest environmental challenges. The Earthshot Prize will be awarded every year for the next decade, discovering a total of 50 Winners.
Five of these 15 Finalists will be awarded The Earthshot Prize and will win £1million in Prize funding for the best solutions of the five Earthshot goals: Protect and Restore Nature; Clean our Air; Revive our Oceans; Build a Waste-free World; and Fix our Climate . The Winners will be announced during an awards ceremony on 17th October from London’s Alexandra Palace, broadcast in the UK on BBC One and globally on Discovery+.
The Earthshot Prize Finalists for 2021 are:
Protect and Restore Nature:
- Pole Pole Foundation, Democratic Republic of Congo
An inspiring community-led model of conservation that protects gorillas and local livelihoods.
- The Republic of Costa Rica
A pioneering scheme paying local citizens to restore natural ecosystems that has led to a revival of the rainforest.
- Restor, Switzerland
A ground-breaking online platform connecting and empowering local conservation projects.
Clean our Air:
- The Blue Map App, China
China’s first public environmental database enabling citizens to hold polluters to account.
- Takachar, India
A pioneering technology to create profitable products from agricultural waste and put a stop to the burning of crops.
- Vinisha Umashankar, India
A 14-year-old innovator and activist who has designed a solar-powered ironing cart with the potential to improve air quality across India.
Revive our Oceans:
- Coral Vita, Bahamas
A truly cutting-edge breakthrough in coral farming that can restore our world’s dying coral reefs.
- Living Seawalls, Australia
Innovative and replicable seawall panels bringing marine life back to coastal sea defences.
- Pristine Seas, USA
An unprecedented global conservation programme protecting 6.5 million square km of the world’s ocean.
Build a Waste-Free World:
- The City of Milan Food Waste Hubs, Italy
A city-wide initiative that has dramatically cut waste while tackling hunger.
- Sanergy, Kenya
A circular sanitation solution that converts human waste into safe products for local farmers.
- WOTA BOX, Japan
A tiny water treatment plant that turns 98% of wastewater into clean water.
Fix our Climate:
- AEM Electrolyser, Thailand/Germany/Italy
An ingenious green hydrogen technology developed to transform how we power our homes and buildings.
- Reeddi Capsules, Nigeria
Solar-powered energy capsules making electricity affordable and accessible in energy-poor communities.
- SOLbazaar, Bangladesh
The world’s first peer-to-peer energy exchange network in a country on the front-line of climate change.
All 15 Finalists will receive support from The Earthshot Prize Global Alliance Members, an unprecedented network of global businesses, who will help scale their solutions for even greater impact.
Of these 15 Finalists, the five Winners will be selected by The Earthshot Prize Council, a diverse team of influential individuals which includes: HRH Prince William, Her Majesty Queen Rania Al Abdullah of Jordan, Sir David Attenborough, Dr Ngozi Okonjo-Iweala, Indra Nooyi, Shakira Mebarak, Christiana Figueres, Luisa Neubauer, Cate Blanchett, Yao Ming, Daniel Alves Da Silva, Ernest Gibson, Hindou Oumarou Ibrahim, Jack Ma, and Naoko Yamazaki.
In the run-up to the prize-giving ceremony on 17 October, BBC and Discovery will release a 5-part documentary series THE EARTHSHOT PRIZE: REPAIRING OUR PLANET, featuring Earthshot Prize Council Members including Prince William, Shakira Mebarak, Daniel Alves Da Silva and Sir David Attenborough.
For more information about the Finalists and The Earthshot Prize, visit: www.earthshotprize.org , email Claire Straw: TEPmedia@freuds.com, download media pack here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210917005454/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
